Dr Sarah Needleman

Job title

Consultant clinical oncologist.

Lead for radiotherapy.

Director of medical education.

Qualifications

MBBS BSc MRCP FRCR MSc PGCert FHEA

GMC Number

6054260

Contact details

PA/secretary phone number: Wasamunu Sitali - 020 7472 6767

PA/secretary email address: wasamunu.sitali@nhs.net

Private practice phone number: Angie Fisher - 020 7830 2169

Private practice email address: angiefisher@nhs.net

Related services

Cancer services

Biography

Dr Sarah Needleman is principal investigator for breast and urology cancer trials and is committed to delivering high-quality, individualised patient care. She has an MSc in oncology and has published oncological manuscripts related to breast and pelvic malignancy. She is passionate about education, and has been awarded education fellowships, undertaken educational research and published related manuscripts.

Publications

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol Attard G, Murphy L, Clarke NW, Cross W, et al Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.Lancet. 2022 Jan 29;399(10323):447-460.

A Phase II, Open-label study to assess safety and management change using 68Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study Afaq A, Payne H, Davda R, Hines J, Cook GJR, Meagher M, Priftakis D, Warbey VS, Kelkar A, Orczyk C, Mitra A, Needleman S, Ferris M, Mullen G, Bomanji J.J Nucl Med. 2021 Mar 19;62(12):1727-34.

Neutrophil-to-lymphocyte ratio (NLR) as a prognostic indicator of treatment response to novel hormones in metastatic castrate-resistant prostate cancer: Real-world data from a single institution E Scott, K Pasciuti, M Kubiak, G Marks, S Needleman, K Smith, M Prentice Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021) 52-52.

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncol. 2018 Nov;19(11):1516-1529 Lancet Oncol. 2018 Dec;19(12):e668. PMID:30337220.Velikova G, Williams LJ, Willis S, Dixon JM, Loncaster J, Hatton M, Clarke J,Kunkler IH, Russell NS; MRC SUPREMO trial UK investigators.

Radiation hazards in pregnancy and methods of prevention Needleman SJ, Powell ME Best Practice & Research Clinical Obstetrics & Gynaecology Oct 2015.

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer JS Vaidya, M Bulsara, M Baum, F Wenz, S Massarut et al- BMJ, 2020.

Hormone Receptor Positive Early Breast Cancer: What Role for Aromatase Inhibitors? Dewdney A, Needleman S Clinical Medicine Reviews in Oncology 2010.

Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer Needleman SJ, Tobias JS. Expert Rev Anticancer Ther. 2008 Dec;8(12): 1871-81.

Aromatase inhibitors in early hormone receptor-positive breast cancer : what is the optimal initiation time for the maximum benefit? Needleman SJ, Tobias JS. Drugs. 2008;68(1):1-15.

The Shift Towards Digital Appointments: the response to Covid -19 Affecting Uro-Oncology E Scott, M Kubiak, S Needleman, G Marks, , K Smith, M Prentice Clinical Oncology supplement, July 2020.

A Single-centre Audit of Time from Surgery to Adjuvant Radiotherapy in Breast Cancer Patients Treated at the Royal Free Hospital K Durno, R Chandler, S Needleman. Clinical Oncology supplement, 2020.

A Single-centre, Retrospective Audit of Adherence to the Updated Royal College of Radiology (RCR) Guidelines for the Treatment Duration of Adjuvant Breast K Durno, A Chander, SNeedlema. Clinical Oncology Supplement, 2020.

Post-mastectomy Radiotherapy Bolus Across the North and East London Radiotherapy Network E Scott, S Needleman - Clinical Oncology Supplement,, 2020.

The Use of the Virtual Environment for Radiotherapy Training (VERT) Improves Understanding and Reduces Anxiety in Patients Undergoing Breast Radiotherapy: a single centre experience V Gandhi, S Kuthpady, S Needleman – Clinical Oncology Supplement 2020.

Deep Inspiratory Breath Hold Technique to Reduce Cardiotoxicity when Delivering Left Breast/Internal Mammary Chain Radical Radiotherapy: Obstacles to compliance A Chander, J Iqbal, S Needleman - Clinical Oncology Supplement, 2019.

Use of Virtual Reality in patient education improves understanding of radiotherapy treatment and reduces anxiety: a retrospective single-centre study NCRI 2018 Vanita Gandhi, Shriniva Kuthpady, Sarah Needleman.

Virtual Reality: Enhancing the prostate cancer patient’s experience of radiotherapy Vanita Gandhi, Kuthpady Shrinivas, Sarah Needleman BMJ Leader 2018.

The use of complementary and alternative medicines (CAM) in brain tumour patients Needleman SJ ,Wasim Z, Kassab S, Short SC European Association for Neurooncology (EANO) Sept 2010.